Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant...

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Posttransplant lymphoproliferative disorder (PTLD) is a serious risk for transplant recipients, often presenting as Epstein-Barr Virus (EBV)-associated diffuse large B cell lymphoma (DLBCL).
• Understanding the biological distinctions between EBV-positive and EBV-negative PT-DLBCL is crucial for targeted therapies.

Purpose of the Study:

• To characterize the clinicopathological and molecular-genetic features of PT-DLBCL.
• To determine if EBV(+) and EBV(-) PT-DLBCL exhibit significant biological differences.

Main Methods:

• Gene expression profiling was conducted on 48 DLBCL samples (33 PT-DLBCL, 15 immunocompetent DLBCL).
• Unsupervised hierarchical analysis and inference analysis were used to identify molecular signatures and immune responses.

Main Results:

• Hierarchical analysis revealed sample clustering based on EBV status, not immune status.
• EBV(+) PT-DLBCL displayed a unique viral response signature, differentiating it from EBV(-) PT-DLBCL and immunocompetent DLBCL.
• A broad EBV latency profile (LMP1+/EBNA2+) was linked to increased inflammatory responses, and innate/tolerogenic immune responses were implicated in EBV(+) PT-DLBCL.

Conclusions:

• EBV status is the primary determinant in the pathogenesis of EBV(+) PT-DLBCL.
• EBV(+) PT-DLBCL has distinct molecular and immunological characteristics compared to EBV(-) DLBCL.